Biofrontera Inc. BFRI

BFRI Company Overview

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on the commercialization of dermatological products, particularly therapies used in the treatment of non-melanoma skin cancers and chronic skin conditions. The company operates within the dermatology and oncology-supportive healthcare sectors and is publicly traded on Nasdaq under the ticker BFRI. Its primary revenue driver is the commercialization of prescription photodynamic therapy products and related medical devices used by dermatologists in outpatient clinical settings. The company’s core commercial products include Ameluz® (aminolevulinic acid hydrochloride gel), a prescription drug used with photodynamic therapy for actinic keratosis, and the BF-RhodoLED® lamp platform used to activate the therapy.

Biofrontera Inc. was established as the U.S. commercial entity associated with Germany-based Biofrontera AG and later became an independent publicly listed company in the United States. The company evolved from a distribution and commercialization model centered on licensed dermatology products into a broader dermatology-focused commercial platform. Its strategic positioning is tied to physician-focused sales infrastructure, specialization in photodynamic therapy, and regulatory-approved dermatologic therapies that address high-incidence skin conditions associated with aging populations and sun exposure.